Product Description
Mechanisms of Action: Cell Wall Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Nasal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Destiny Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Surgical Wound Infection|Staphylococcal Infections|Communicable Diseases
Phase 1: Staphylococcal Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
XF-73B07 | P2 |
Completed |
Staphylococcal Infections|Communicable Diseases|Surgical Wound Infection |
2021-01-04 |
53% |
2022-06-02 |
Primary Endpoints|Start Date|Treatments |
HHSN272201500007I | P1 |
Completed |
Staphylococcal Infections |
2015-08-01 |
2019-03-19 |
Treatments |
|
XF-73B03 | P2 |
Completed |
Staphylococcal Infections |
2014-11-01 |
2019-03-20 |
Treatments |